How does tigecycline cause liver injury?

How does tigecycline cause liver injury?

Tigecycline triggers liver injury mainly through direct hepatocyte toxicity. The drug accumulates inside liver cells and disrupts mitochondrial function, leading to oxidative stress and cell death. This mechanism produces a mixed cholestatic-hepatocellular pattern of enzyme elevation rather than a purely immune-mediated reaction.

Why does this injury appear after several days of treatment?

Liver enzymes often rise between day 3 and day 10 of therapy. The delay reflects the time needed for intracellular drug levels to reach a toxic threshold and for hepatocyte turnover to slow enough for enzyme release to become detectable.

What blood-test changes do clinicians see?

ALT and AST commonly increase two- to five-fold; alkaline phosphatase and bilirubin may rise more modestly. Most cases remain asymptomatic and resolve within one to two weeks after stopping the drug, but severe hepatocellular necrosis has been reported in patients with prolonged courses or pre-existing liver disease.

Who faces the greatest risk?

Patients receiving high daily doses, those treated longer than two weeks, and individuals with baseline hepatic impairment show higher rates of enzyme elevation. Concomitant hepatotoxic drugs such as acetaminophen or rifampin can amplify the effect.

Can the injury be prevented or reversed?

Dose reduction to 25 mg twice daily in Child-Pugh C patients lowers exposure and reduces hepatotoxicity. Routine monitoring of liver enzymes on days 3–5 and weekly thereafter allows early discontinuation if ALT exceeds five times the upper limit of normal. No specific antidote exists; management is supportive.

How does tigecycline compare with other tetracyclines?

Minocycline and doxycycline produce more autoimmune-type hepatitis, whereas tigecycline’s profile is dominated by dose-dependent mitochondrial toxicity. This difference influences monitoring intensity and the decision to switch agents when liver tests rise.

When do patents and generics affect access to safer dosing?

Tigecycline’s original composition-of-matter patent expired in 2015; several generic versions are now marketed. Lower-cost generics have enabled wider use of the reduced-dose regimens recommended for hepatic impairment, though formulation consistency varies among suppliers.